The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Bristol Myers Squibb today announced the U.S. Food and Drug Administration has granted accelerated approval of Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Breyanzi ® offers diffuse large B-cell lymphoma patients facing relapse or refractory disease earlier access with more personalized second-line treatment options. In the pivotal Phase 3 TRANSFORM ...

BREYANZI can lower one or more types of your blood cells (red blood cells, white blood cells, or platelets). After treatment, your healthcare provider will test your blood to check for this.

B-cell aplasia and hypogammaglobulinemia can occur in patients receiving BREYANZI. In clinical trials of BREYANZI, hypogammaglobulinemia was reported as an adverse reaction in 10% of patients.

Bristol-Myers Squibb (NYSE:BMY) posted second-quarter earnings that surpassed analyst expectations, largely thanks to robust ...

PRINCETON, N.J., June 03, 2024--BMS' Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting ...

When your BREYANZI is ready, your healthcare provider will give it to you through a catheter placed into your vein (intravenous infusion). BREYANZI is given as infusions of 2 different cell types.